Comparative Pharmacology
Head-to-head clinical analysis: UTICILLIN VK versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UTICILLIN VK versus VEETIDS 125.
UTICILLIN VK vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic